Remove Circulation Remove Ischemia Remove Peripheral Arterial Disease
article thumbnail

Abstract 4147504: Efficacy and Safety of Vorapaxar in Patients with Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4147504-A4147504, November 12, 2024. There are discrepancies in the literature regarding whether vorapaxar alleviates ischemic outcomes and increases bleeding in patients with peripheral arterial disease (PAD).Purpose:The to 0.97, I2: 0%) compared to placebo.

article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

article thumbnail

New Dodero Center at UH will Revolutionize Limb Salvage

DAIC

Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheral artery disease and diabetes.

article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Circulation, vol. 2024, [link].

article thumbnail

Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD

Circulation

Circulation, Volume 148, Issue 24 , Page 1919-1928, December 12, 2023. The effect has not been described in patients undergoing endovascular LER.METHODS:The VOYAGER PAD trial randomized 6564 patients with symptomatic peripheral artery disease to a double-blinded treatment with 2.5 0.98];Pinteraction=0.43).

article thumbnail

University Hospitals Receives Grant for New Limb Preservation Center

DAIC

Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheral artery disease and diabetes.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Inflammation driven by signaling cytokines, circulating immune cells, adhesion molecules, and oxidized low-density lipoprotein cholesterol (LDL-C) leads to atherosclerotic plaque development, plaque progression, and eventual rupture.14,15 2019 Sep 10;140(11):e649-e650] [published correction appears in Circulation. Circulation.